Rectal Cancer
967
179
224
364
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
82 trials with published results (8%)
Research Maturity
364 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.4%
62 terminated out of 967 trials
85.4%
-1.1% vs benchmark
8%
79 trials in Phase 3/4
23%
82 of 364 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 364 completed trials
Clinical Trials (967)
Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer
Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)
Radiomics in Rectal Cancer
Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
Transanal Irrigation for the Management of LARS
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
Self Regulation Hypnotic Intervention for Pain and Anxiety During Rectal Brachytherapy
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer